Capricor Therapeutics, Inc. (CAPR) vs Contineum Therapeutics, Inc. (CTNM)
A side-by-side comparison of Capricor Therapeutics, Inc. and Contineum Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CAPR
Capricor Therapeutics, Inc.
$7.78HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CTNM
Contineum Therapeutics, Inc.
$12.72HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CAPR vs CTNM
growth of $100 · dividends reinvested · last 2yCAPR +15.8% (+7.6%/yr)CTNM -17.4% (-9.1%/yr)CAPR compounded faster over this window
CAPR CTNM
CAPR vs CTNM: by the numbers
- •CTNM is the larger company ($479M vs $447M market cap).
Metrics side by side
Valuation
| Metric | CAPR | CTNM |
|---|---|---|
| P/B ratio | 1.82 | 2.00 |
| EV / EBITDA | 0.44 | N/A |
Profitability
| Metric | CAPR | CTNM |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -52.56% | -24.02% |
| ROIC | -40.25% | -27.22% |
Growth (annualized)
| Metric | CAPR | CTNM |
|---|---|---|
| Total return CAGR (5Y) | 15.17% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.